On June 10, 2019 Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), reported two presentations at the 24th Congress of the European Hematology Association (EHA) (Free EHA Whitepaper) being held June 13-16, 2019 in Amsterdam, Netherlands (Press release, Onconova, JUN 10, 2019, View Source [SID1234536974]). Dr. Steven Fruchtman, President & CEO, Dr. Ric Woodman, CMO, and Dr. Ronnee Adesanya, VP Medical Affairs, will be attending the conference.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
DETAILS OF THE PRESENTATIONS:
Title: PHASE II STUDY OF ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS)
Format: ORAL PRESENTATION: Abstract S839
Location – Elicium 1
Date/Time: Saturday, June 15 / 12:00 – 12:15
Presenter: Shyamala C. Navada, MD
Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
Title: RIGOSERTIB MODULATES HEMATOPOIESIS GENE SIGNALING PATHWAYS ALONE OR IN SEQUENCES
COMBINATION WITH AZACITIDINE ON MDS CELLS IN VITRO
Format: POSTER PRESENTATION: Abstract PS1332
Location – Poster area
Date/Time: Saturday, June 15 / 17:30 – 19:00
Presenter: Lewis R. Silverman, MD
Tisch Cancer Institute, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
A copy of the poster and oral presentation slides will be available immediately following the event by visiting the Scientific Presentations section of Onconova’s website: View Source